Russ Conroy

The approval status of lurbinectedin as first-line care for those with small cell lung cancer will not be impacted following results from the LAGOON trial.

Ajay K. Nooka, MD, MPH, FACP, discusses how results from the MonumenTAL-6 trial build upon prior studies assessing bispecific antibodies in multiple myeloma.

Data from the phase 3 EXCALIBER-RRMM trial support the FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone in this multiple myeloma population.

Data presented at the 2026 AACR Annual Meeting demonstrated the promise of blood-based lung cancer detection via SimpleScreen Lung.

Data from the SAFFRON trial may represent a critical advance in the management of EGFR-mutated NSCLC with MET-driven resistance.

A nurse practitioner, clinical social worker, and patient discuss navigating treatment-related concerns and psychosocial considerations in multiple myeloma.

Bispecific antibodies “will form the standard backbone agents for multiple myeloma therapies,” according to Hans Lee, MD.

Two teams of multiple myeloma experts debate the use of early CAR T-cell therapies and bispecific antibodies based on key trial data and various hot topics.

Sunil Singhal, MD, discussed how fluorescence imaging via abenacianine helps surgeons visualize tumors missed during lung cancer surgery.

Surbhi Sidana, MD, discusses the first CELMoD and first MRD-based approval, iberdomide, in relapsed/refractory multiple myeloma.